stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
30.60
0.46
+1.53%
Follow VERA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 2 | 6 | +394.1% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (12) | (53) | (33) | (89) | (96) | (152) | (300) | (402) | +71.3% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (12) | (53) | (33) | (89) | (96) | (152) | (300) | (402) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (40.13) | (166.93) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) | (5.86) | (30.2%) | ||||||
| Cash flow | — | — | — | (34.84) | (108.78) | (1.76) | (2.54) | (2.16) | (2.43) | (3.75) | (4.71) | (31.0%) | ||||||
| Capex | — | — | — | (0.42) | (0.13) | (0.37) | 0.00 | 0.00 | (0.02) | (0.01) | 0.00 | (46.6%) | ||||||
| Free cash flow | — | — | — | (35.27) | (108.91) | (2.14) | (2.55) | (2.16) | (2.45) | (3.76) | (4.72) | (31.1%) | ||||||
| Book value | — | — | — | 12.01 | 156.96 | 5.18 | 2.89 | 2.38 | 10.43 | 9.41 | 5.68 | (4.0%) | ||||||
| Shares, m | — | — | — | 0 | 0 | 13 | 27 | 43 | 55 | 64 | 68 | +145.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (10) | (35) | (24) | (68) | (92) | (135) | (241) | (339) | +69.2% | |||||
| Capex | — | — | — | 0 | 0 | (5) | 0 | 0 | (1) | (1) | 0 | +30.9% | ||||||
| Free cash flow | — | — | — | (10) | (35) | (29) | (68) | (92) | (136) | (242) | (339) | +68.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 52 | 75 | 100 | 150 | 626 | 675 | 479 | +154.2% | |||||
| Net debt | — | — | — | (3) | (54) | (75) | (90) | (111) | (590) | (640) | (424) | +142.0% | ||||||
| Shareholders’ equity | — | — | — | 4 | 50 | 70 | 77 | 102 | 577 | 605 | 408 | +135.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (440.59) | (178.24) | (47.16) | (82.77) | (62.54) | (36.61) | (43.10) | (72.32) | +397.5 pt | |||||
| ROIC | — | — | — | (2,065.09) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +2,065.1 pt | ||||||
| ROE | — | — | — | 18.83 | 84.85 | 330.12 | (121.58) | (107.50) | (44.83) | (50.71) | (91.75) | (69.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 8 | 17 | 46 | 51 | 112 | 249 | — | +98.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Vera Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc | $3.0B | 16.7× | 14.0× | +5.12% (above 0%: growing) | +46.67% (above 0%: growing) | +1,709.49% (above 0%: growing) | 70.81% | 48.02% | Compare |
| VCEL Vericel Corporation | $2.7B | 77.8× | 72.9× | +26.47% (above 0%: growing) | +180.00% (above 0%: growing) | −19.39% (below 0%: shrinking) | 73.34% | 14.27% | Compare |
| PVLA Palvella Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.2B | — (loss-making) | — (loss-making) | −95.35% (below 0%: shrinking) | +198.85% (above 0%: growing) | +18.22% (above 0%: growing) | 25.95% | (982.91%) | Compare |
| VERA Vera Therapeutics, Inc. | $2.2B | — (loss-making) | — | — | n/m | −82.47% (below 0%: shrinking) | 0.00% | 0.00% | |
| AUPH Aurinia Pharmaceuticals Inc | $2.2B | 6.8× | 17.6× | +13.93% (above 0%: growing) | 0.00% | +4.41% (above 0%: growing) | 90.08% | 40.74% | Compare |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| BHVN Biohaven Ltd. | $2.1B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +26.55% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.2B | 16.7× | 17.6× | +9.53% | +113.34% | −7.49% | 81.71% | 0.00% |
Pay and ownership Proxy statement filed 9 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 6.99m | 9.13m | 261.70 |
| 2024 | 5.65m | 31.24m | 218.55 |
| 2023 | 3.43m | 1.99m | 79.48 |
Ownership
Directors and executive officers, together
15.90%
Avoro Capital Advisors LLC
7.80%
T. Rowe Price Associates, Inc.
7.60%
Patrick Enright
7.60%
Entities affiliated with Longitude Venture Partners IV, L.P.
7.50%
Deep Track Capital, LP
5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement